Experimental Regenerative Therapy for Heart Failure Lowers Major Cardiac Events & Death but Not Hospitalizations

Mesoblast’s (ASX: MSB; Nasdaq: MESO) DREAM-HF clinical trial investigates regenerative therapy for heart failure that led to a reduction in major cardiac events and death, however not a reduction in hospitalization for heart failure events.  Focused on adults with heart failure, the study team recently disclosed the results from a randomized, controlled Phase 3 clinical trial of investigational stem cell therapy called rexlemestrocel-L in 565 patients with New York Heart Association (NYHA) class II and class III chronic heart failure (CHF) with reduced ejection fraction (HFrEF). Presented recently as a late breaking presentation at the American Heart Association (AHA) annual Scientific Sessions in an event titled ‘Building on the Foundations of Treatment: Advances in Heart Failure Therapy’ Dr. Emerson Perin, co-principal investigator and Medical Director of Texas Heart Institute as well as Clinical Professor, Baylor College of Medicine, presented new results from the study evidencing a significant relationship between presence of systemic inflammation as quantified by high-sensitivity C-reactive protein (hs-CRP) and treatment benefit with the investigational stem cell therapy...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee